CRP, Human, ELISA kit

Catalog #: HK358

Quantity: 1 x 96 det.

Availability: In stock

Description: CRP, Human, ELISA kit

C-Reactive Protein (CRP) is an acute-phase protein, produced exclusively in the liver. Interleukin-6 is the mediator for the synthesis by the hepatocytes- of CRP, a pentamer of approximately 120.000 Daltons. CRP is present in the serum of normal persons at concentrations ranging up to 5mg/l. The protein is produced by the fetus and the neonate and it does not pas the placental barrier, as such it can be used for the early detection of neonatal sepsis.
Because febrile phenoena, leukocyte count and erythrocyte sedimentation rate (ESR) are often misleading, investigators now prefer a quantitative CRP determination as a marker for acute inflammation and tissue necrosis. Within 6 hours of an acute inflammatory challenge the CRP level starts to rise.
Serum concentration of CRP increases significantly in cases of both infectious and non-infectious inflammation, of tissue damage and necrosis and in the presence of malignant tumours.-- CRP is present in the active stages of inflammatory disorders like rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, psoriatric arthropathy, systemic lupus erythematosus, polyarteritis, ulcerative colitis and Crohn's disease.
Widespread malignant disease with carcinoma of the lung, stomach, colon, breast, prostate and pancreas, Hodgkin's disease, non-Hodgkin's lymphoma and lymphosarcoma will give rise to high levels of CRP resulting from tissue damage by invading tumor cells. CRP, therefore may be used to monitor malignancy.
The CRP-level increases dramatically following microbial infections, and this may be particularly helpful for the diagnosis and monitoring of bacterial septicemia in neonates and other immunocompromised patients at risk. In children, CRP is useful for differential diagnosis of bacterial and viral meningitis.
Because the biological half-life of this protein is only 24 hours, CRP accurately parallels the activity of the inflammation process and the CRP concentration decreases much faster than ESR or any other acute phase parameter, which is particularly useful in monitoring appropriate treatment of bacterial diseases with antibiotics.
C-Reactive Protein measurements during the early and late post transplant period of bone marrow and organ transplantations is particularly useful in the management of interfering infections in these immunosuppressed patients.

Specifications

Catalog number HK358
Product type Assays
Quantity 1 x 96 det.
Standard range 5 to 100 ng/ml
Detection level 5 ng/ml
Working volume 100 µl/well
Species Human
Application The human CRP ELISA kit is to be used for the in vitro quantitative determination of human CRP in serum and plasma.
Disease Gastroenterology, Infectious diseases
Principle The human CRP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 1 hour and 10 minutes. The efficient format of 1 plate with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibodies recognizing human CRP. Peroxidase conjugate antibody will bind to the captured human CRP. Peroxidase conjugate antibody will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of Sulfuric acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human CRP standards (log). The human CRP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
References 1. Powell LJ; C - Reactive Protein - a Review Am. J. Med. Technol., 1979, 87: 138
2. Gewurz H et al; C-Reactive Protein and the Acute Phase Response. Adv in Int Med, 1982, 27: 345
3. Helgeson N et al; C - Reactive Protein : Laboratory Medicine, Vol. 2 (Race G. J., Ed.), Harper & Row, Hagerstown, chapter 29 (1973).
4. Johnson HL et al; Applications of acute phase reactants in infectious diseases J. Microbiol. Immunol. Infect. 1999, 32: 73